Center for Human Genetics, K.U. Leuven, Gasthuisberg, Herestraat 49, Box 602, B-3000 Leuven, Belgium.
Haematologica. 2010 Mar;95(3):509-13. doi: 10.3324/haematol.2009.014761.
We report 2 ALK-positive large B-cell lymphoma cases showing granular cytoplasmic and cytoplasmic/nuclear ALK immunostaining in which cryptic ALK rearrangements were identified by fluorescent in situ hybridization and molecular analysis. In the first case, the ALK-involving t(2;3)(p23;q27) masked the cryptic SEC31A-ALK fusion generated by an insertion of the 5' end of SEC31A (4q21) upstream of the 3' end of ALK. This rearrangement was associated with loss of the 5' end of ALK and duplication of SEC31A-ALK on der(20). In the second case with complex rearrangements of both chromosomes 2, a submicroscopic NPM1-ALK fusion created by insertion of the 3' end of ALK into the NPM1 locus was evidenced. Further studies of SEC31A-ALK showed that this variant fusion transforms IL3-dependent Ba/F3 cells to growth factor independence, and that the ALK inhibitor TAE-684 reduces cell proliferation and kinase activity of SEC31A-ALK and its downstream effectors ERK1/2, AKT, STAT3 and STAT5.
我们报告了 2 例ALK 阳性的大 B 细胞淋巴瘤病例,其细胞质和细胞质/核ALK 免疫染色呈颗粒状,通过荧光原位杂交和分子分析鉴定出隐匿性ALK 重排。在第一个病例中,涉及 t(2;3)(p23;q27)的 ALK 掩盖了由 SEC31A(4q21)的 5' 端插入 ALK 的 3' 端产生的隐匿性 SEC31A-ALK 融合。这种重排与 ALK 的 5' 端缺失和 SEC31A-ALK 在 der(20)上的重复有关。在第二个病例中,两条 2 号染色体均发生复杂重排,通过将 ALK 的 3' 端插入 NPM1 基因座,产生了亚微观的 NPM1-ALK 融合。进一步研究 SEC31A-ALK 表明,这种变体融合使依赖于 IL3 的 Ba/F3 细胞转化为生长因子独立性,ALK 抑制剂 TAE-684 可降低 SEC31A-ALK 及其下游效应物 ERK1/2、AKT、STAT3 和 STAT5 的细胞增殖和激酶活性。